+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years - 80Years
All Genders
ID06825559

Study to Assess Pharmacokinetics, Safety, and Tolerability of Saroglitazar Magnesium in Adults with Moderate Hepatic Impairment Due to Cholestatic Liver Disease

Led by Zydus Therapeutics Inc. · Updated on 2026-09-14

6

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are investigating the pharmacokinetics, safety, and tolerability of Saroglitazar Magnesium given every other day to adults with moderate liver impairment caused by cholestatic liver disease and cirrhosis. This phase 1, open-label, single-arm study aims to understand how the drug behaves in the body and its safety profile in this specific group of patients. Participants receive Saroglitazar Magnesium 1 mg orally in the morning before breakfast without food, every other day for 29 days. The study focuses on detailed blood sampling on Day 1 and Day 29 to measure drug levels at multiple time points to assess how the drug is absorbed, distributed, metabolized, and eliminated. During the trial, participants undergo frequent pharmacokinetic blood tests to measure drug concentration and metabolism markers over 48 hours after dosing on specific days. Researchers also monitor safety by recording any adverse events throughout the 35-day study period. Laboratory tests, including liver enzyme levels, are evaluated from baseline through the treatment to assess changes and tolerability.

CONDITIONS

Brief Title

Evaluate PK & Safety of Saroglitazar in Subjects With Moderate Hepatic Impairment Due to Cholestatic Liver Disease

Research Team

F

Farheen Shaikh

D

Deven Parmar

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here